blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2117524

EP2117524 - USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.07.2020
Database last updated on 14.09.2024
FormerThe patent has been granted
Status updated on  12.07.2019
FormerGrant of patent is intended
Status updated on  05.07.2019
FormerExamination is in progress
Status updated on  25.06.2019
FormerGrant of patent is intended
Status updated on  26.03.2019
FormerExamination is in progress
Status updated on  06.12.2016
Most recent event   Tooltip24.06.2022Lapse of the patent in a contracting state
New state(s): CY, HU, MT		published on 27.07.2022  [2022/30]
Applicant(s)For all designated states
National Research Council of Canada
1200 Montreal Road
Ottawa, ON K1A 0R6 / CA
[2019/33]
Former [2009/47]For all designated states
National Research Council of Canada
1200 Montreal Road
Ottawa, ON K1A OR6 / CA
Inventor(s)01 / KONISHI, Yasuo
21 Chaudiere St.
Kirkland, Quebec H9H 4C8 / CA
02 / MAGOON, Joanne
1983 Richardson
Montréal, Québec H3K 1G8 / CA
03 / JARUSSOPHON, Suwatchai
84 moo 5 Banglaung
Muang, Pathumthani 12000 / TH
 [2009/47]
Representative(s)Glück Kritzenberger Patentanwälte PartGmbB
Franz-Mayer-Str. 16a
93053 Regensburg / DE
[N/P]
Former [2019/33]Glück Kritzenberger Patentanwälte PartGmbB
Hermann-Köhl-Strasse 2a
93049 Regensburg / DE
Former [2013/13]Graf Glück Kritzenberger
Hermann-Köhl-Strasse 2a
93049 Regensburg / DE
Former [2009/47]Zipse Habersack Kritzenberger
Hermann-Köhl-Straße 2a
93049 Regensburg / DE
Application number, filing date08706338.429.01.2008
[2009/47]
WO2008CA00191
Priority number, dateUS200789781407P29.01.2007         Original published format: US 89781407 P
US200792467407P25.05.2007         Original published format: US 92467407 P
[2019/34]
Former [2019/31]US20070897814P29.01.2007
US200792467407P25.05.2007
Former [2009/47]US20070897814P29.01.2007
US20070924574P25.05.2007
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2008092257
Date:07.08.2008
Language:EN
[2008/32]
Type: A1 Application with search report 
No.:EP2117524
Date:18.11.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 07.08.2008 takes the place of the publication of the European patent application.
[2009/47]
Type: B1 Patent specification 
No.:EP2117524
Date:14.08.2019
Language:EN
[2019/33]
Type: B8 Corrected title page of specification 
No.:EP2117524
Date:25.09.2019
[2019/39]
Search report(s)International search report - published on:CA07.08.2008
(Supplementary) European search report - dispatched on:EP05.06.2012
ClassificationIPC:A61K31/137, A61K31/222, A61K31/36, A61P9/00, A61K9/00
[2019/15]
CPC:
A61K31/137 (EP,US); A61K31/216 (US); A61K31/222 (EP,US);
A61K31/36 (EP,US); A61K31/445 (US); A61K31/495 (US);
A61K31/522 (US); A61K9/0048 (EP,US); A61P27/02 (EP);
A61P3/10 (EP); A61P9/00 (EP) (-)
Former IPC [2009/47]A61K31/137, A61K31/216, A61K31/222, A61K31/36, A61K31/445, A61K31/495, A61K31/522, A61P9/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2019/33]
Former [2009/47]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:VERWENDUNG VON CATECHOLAMINEN UND ENTSPRECHENDEN VERBINDUNGEN ALS MITTEL GEGEN ANGIOGENESE[2009/47]
English:USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS[2009/47]
French:UTILISATION DE CATECHOLAMINES ET DE COMPOSES ASSOCIES COMME AGENTS ANTI-ANGIOGENIQUES[2009/47]
Entry into regional phase31.08.2009National basic fee paid 
31.08.2009Search fee paid 
31.08.2009Designation fee(s) paid 
31.08.2009Examination fee paid 
Examination procedure31.08.2009Examination requested  [2009/47]
04.12.2012Amendment by applicant (claims and/or description)
18.04.2013Despatch of a communication from the examining division (Time limit: M06)
29.11.2013Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
29.01.2014Reply to a communication from the examining division
26.07.2016Despatch of a communication from the examining division (Time limit: M04)
05.12.2016Reply to a communication from the examining division
27.03.2019Communication of intention to grant the patent
18.06.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
04.07.2019Fee for grant paid
04.07.2019Fee for publishing/printing paid
04.07.2019Receipt of the translation of the claim(s)
18.07.2019Request for correction of the decision to grant filed
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  18.04.2013
Opposition(s)03.06.2020No opposition filed within time limit [2020/33]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
29.01.2014Request for further processing filed
29.01.2014Full payment received (date of receipt of payment)
Request granted
14.02.2014Decision despatched
Fees paidRenewal fee
01.02.2010Renewal fee patent year 03
31.01.2011Renewal fee patent year 04
31.01.2012Renewal fee patent year 05
31.01.2013Renewal fee patent year 06
31.01.2014Renewal fee patent year 07
02.02.2015Renewal fee patent year 08
01.02.2016Renewal fee patent year 09
05.01.2017Renewal fee patent year 10
29.01.2018Renewal fee patent year 11
07.11.2018Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.01.2008
CY14.08.2019
CZ14.08.2019
DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
MC14.08.2019
MT14.08.2019
RO14.08.2019
SI14.08.2019
SK14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
IS14.12.2019
LU29.01.2020
[2022/27]
Former [2020/46]CZ14.08.2019
DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
MC14.08.2019
RO14.08.2019
SI14.08.2019
SK14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
IS14.12.2019
LU29.01.2020
Former [2020/39]CZ14.08.2019
DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
MC14.08.2019
RO14.08.2019
SI14.08.2019
SK14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
IS14.12.2019
Former [2020/37]CZ14.08.2019
DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
RO14.08.2019
SI14.08.2019
SK14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
IS14.12.2019
Former [2020/36]CZ14.08.2019
DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
RO14.08.2019
SK14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
IS14.12.2019
Former [2020/26]CZ14.08.2019
DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
RO14.08.2019
SK14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
IS24.02.2020
Former [2020/24]DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
RO14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
IS24.02.2020
Former [2020/23]DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
RO14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
IS14.12.2019
Former [2020/22]DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
IS14.12.2019
Former [2020/17]FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
IS14.12.2019
Former [2020/13]FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
BG14.11.2019
NO14.11.2019
IS14.12.2019
Former [2020/11]FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
BG14.11.2019
NO14.11.2019
Former [2020/10]FI14.08.2019
LT14.08.2019
BG14.11.2019
NO14.11.2019
Former [2020/09]FI14.08.2019
LT14.08.2019
NO14.11.2019
Former [2020/08]LT14.08.2019
NO14.11.2019
Documents cited:Search[I]JPH09136830  (KAGAKU GIJUTSU SHINKO JIGYODAN) [I] 1-6,10-16 * abstract *;
 [X]WO03032969  (CA NAT RESEARCH COUNCIL [CA], et al) [X] 1-6,10-16 * page 2, lines 15-24 * * claims 1-17, 58-76 *;
 [XPL]WO2007109882  (CA NAT RESEARCH COUNCIL [CA], et al) [XP] 1-6,10-14,16 * claims 14-30 * * priority not valid * [L] 1-6,10-14,16;
 [I]WO2006015830  (UNIV LOUVAIN [BE], et al) [I] 1-6,10-14,16 * claims 14, 17-18, 20 *;
 [X]WO9606081  (PFIZER [US], et al) [X] 1-6,11-13 * claims 22-23 * * page 8, lines 6, 11 * * page 55; example 27 *;
 [XI]US5395970  (TUTTLE RONALD R [US], et al) [X] 1-6,10-13 * column 2, lines 30-32 * * claims 1-2 * * example 1 * [I] 15;
 [Y]US2004038972  (DEN HARTOG JACOBUS A J [NL], et al) [Y] 1-6,10-16 * claims 11, 14 * * page 3, paragraph 32 * * page 7, paragraph 69 *;
 [I]  - "Isoproterenol-containing retina protectant - is useful for treating diseases causing injury to retinal cells e.g. diabetes mellitus, etc", DERWENT, (1997), XP002228062 [I] 1-6,10-16 * abstract *
 [I]  - JOHNSON K ET AL, "METABOLISM, PHARMACOKINETICS, AND EXCRETION OF A HIGHLY SELECTIVE N-METHYL-D-ASPARTATE RECEPTOR ANTAGONIST, TRAXOPRODIL, IN HUMAN CYTOCHROME P450 2D6 EXTENSIVE AND POOR METABOLIZERS", DRUG METABOLISM AND DISPOSITION, WILLIAMS AND WILKINS, BALTIMORE, MD, US, (20030101), vol. 31, no. 1, doi:10.1124/DMD.31.1.76, ISSN 0090-9556, pages 76 - 87, XP009069857 [I] 1-6,11,12 * page 77; figure 1; examples Trapoxadil, M13 * * page 76, column right, lines 5-6 *

DOI:   http://dx.doi.org/10.1124/dmd.31.1.76
 [Y]  - COMAI K ET AL, "PHENETHYLAMINE INHIBITORS OF PARTIALLY PURIFIED RAT AND HUMAN PANCREATIC LIPASE", JOURNAL OF PHARMACEUTICAL SCIENCES, (1982), vol. 71, no. 4, ISSN 0022-3549, pages 418 - 421, XP007920652 [Y] 1-6,10-16 * page 420; table I *

DOI:   http://dx.doi.org/10.1002/jps.2600710411
 [A]  - PANDYA N M ET AL, "Angiogenesis-a new target for future therapy", VASCULAR PHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 44, no. 5, doi:10.1016/J.VPH.2006.01.005, ISSN 1537-1891, (20060501), pages 265 - 274, (20060501), XP024970442 [A] 1-6,10-16 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.vph.2006.01.005
 [T]  - Rhodia, "GPS Safety Summary Para trifluoromethylaniline", (20111201), URL: http://www.rhodia.com/en/binaries/GPS_2011_12_v1_Paratrifluoromethylaniline_gb1.pdf, (20120524), XP007920651 [T] 15 * page 2/6 *
 [YD]  - THAKER PREMAL H ET AL, "Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 12, no. 8, doi:10.1038/NM1447, ISSN 1078-8956, (20060801), pages 939 - 944, (20060723), XP002590206 [YD] 1-6,10-16 * last full sentence; page 940, column left *

DOI:   http://dx.doi.org/10.1038/nm1447
 [I]  - NAGARAJAN R ET AL, "A novel catecholamine, arbutamine, for a pharmacological cardiac stress agent", CARDIOVASCULAR DRUGS AND THERAPY, KLUWER ACADEMIC PUBLISHERS, BOSTON, US, (19960101), vol. 10, no. 1, ISSN 0920-3206, pages 31 - 38, XP009159647 [I] 1-6,10-16 * the whole document *

DOI:   http://dx.doi.org/10.1007/BF00051128
International search[AP]WO2007109882  (CA NAT RESEARCH COUNCIL [CA], et al);
 [A]WO03032969  (CA NAT RESEARCH COUNCIL [CA], et al);
 [A]WO2006015830  (UNIV LOUVAIN [BE], et al);
 [A]US2003181354  (ABDULRAZIK MUHAMMAD [IL]);
 [A]  - CHALOTHORN D. ET AL., "Catecholamines augment collateral vessel growth and angiogenesis in hindlimb ischemia", AM. J. PHYSIOL. HEART CIRC. PHYSIOL., (2005), vol. 289, pages H947 - H959, XP008109101

DOI:   http://dx.doi.org/10.1152/ajpheart.00952.2004
ExaminationUS2007021512
by applicant   - BASU, S.; NAGY, J. A.; PAL, S.; VASILE, E.; ECKELHOEFER, I. A.; BLISS, V. S.; MANSEAU, E. J.; DASGUPTA, P. S.; DVORAK, H. F.; MUKH, "The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor", NAT. MED., (2001), vol. 7, pages 569 - 574
    - BENTLEY, G. A.; STARR, J, "The antinociceptive action of some ?-adrenoceptor agonists in mice", BR. J. PHARMACOL, (1986), vol. 88, pages 515 - 521
    - BOULTON, D. W.; FAWCETT, J. P, "p2-Agonist eutomers: A rational option for the treatment of asthma?", AM. J. RESPIR. MED., (2002), vol. 1, pages 305 - 311
    - CHEN, A. S.; TAGUCHI, T.; SUGIURA, M.; WAKASUGI, Y.; KAMEI, A.; WANG, M. W.; MIWA, I, "Pyridoxal-aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats", HORM. METAB. RES., (2004), vol. 36, pages 183 - 187
    - CONWAY, W. D.; MINATORYA, H.; LNDS, A. M.; SHEKOSKY, J. M, "Absorption and elimination profile of isoproterenol III. The metabolic fate of dl-isoproterenol-7-3H in the dog", J. PHARM. SCI., (1968), vol. 57, pages 1135 - 1141
    - CHALOTHORN, D.; ZHANG, H.; CLAYTON, J.A.; THOMAS, S.A.; FABER, J.E, "Catecholamines augment collateral vessel growth and angiogenesis in hindlimb ischemia", AM. J. PHYSIOL. HEART CIRC. PHYSIOL., (2005), vol. 289, pages H947 - H959
    - DEJGAARD, A.; HILSTED, J.; CHRISTENSEN, N.J, "Noradrenaline and isoproterenol kinetics in diabetic patients with and without autonomic neuropathy", DIABETOLOGIA, (1986), vol. 29, pages 773 - 777
    - JARVINEN, T.; JARVINEN, K, "Prodrugs for improved ocular drug delivery", ADV. DRUG DELIVERY REV., (1996), vol. 19, pages 203 - 224
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.